MA41134B1 - Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales - Google Patents
Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections viralesInfo
- Publication number
- MA41134B1 MA41134B1 MA41134A MA41134A MA41134B1 MA 41134 B1 MA41134 B1 MA 41134B1 MA 41134 A MA41134 A MA 41134A MA 41134 A MA41134 A MA 41134A MA 41134 B1 MA41134 B1 MA 41134B1
- Authority
- MA
- Morocco
- Prior art keywords
- prophylaxis
- treatment
- viral infections
- thiazolo
- pyrimidin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 238000011321 prophylaxis Methods 0.000 title abstract 2
- 238000011282 treatment Methods 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title abstract 2
- YDWRPBIUDIYAOX-UHFFFAOYSA-N 5-amino-3,4-dihydro-[1,3]thiazolo[4,5-d]pyrimidine-2,7-dione Chemical compound O=C1NC(N)=NC2=C1SC(=O)N2 YDWRPBIUDIYAOX-UHFFFAOYSA-N 0.000 title 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La présente invention concerne des composés de formule (i), dans laquelle r1, r2 et r3 sont tels que décrits ici, et leurs promédicaments ou leur sel, énantiomère ou diastéréoisomère pharmaceutiquement acceptables de ceux-ci, des compositions comprenant les composés ainsi que des procédés d'utilisation des composés comme agonistes de tlr7 pour le traitement et la prophylaxie d'infections virales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014093224 | 2014-12-08 | ||
| CN2015086987 | 2015-08-14 | ||
| PCT/EP2015/078439 WO2016091698A1 (fr) | 2014-12-08 | 2015-12-03 | Composés 5-amino-6h-thiazolo [4,5-d]pour le traitement et la prophylaxide d'infections virales |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41134A MA41134A (fr) | 2017-10-18 |
| MA41134B1 true MA41134B1 (fr) | 2021-03-31 |
Family
ID=54771116
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA41134A MA41134B1 (fr) | 2014-12-08 | 2015-12-03 | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales |
Country Status (30)
| Country | Link |
|---|---|
| US (4) | US9441008B2 (fr) |
| EP (1) | EP3230298B1 (fr) |
| JP (1) | JP6817217B2 (fr) |
| KR (2) | KR102557560B1 (fr) |
| CN (2) | CN107445980B (fr) |
| AU (1) | AU2015359692B2 (fr) |
| BR (1) | BR112017011941B1 (fr) |
| CA (1) | CA2963717C (fr) |
| CL (1) | CL2017001426A1 (fr) |
| CR (1) | CR20170237A (fr) |
| DK (1) | DK3230298T3 (fr) |
| EA (1) | EA038744B1 (fr) |
| ES (1) | ES2864223T3 (fr) |
| HR (1) | HRP20210454T1 (fr) |
| HU (1) | HUE053704T2 (fr) |
| IL (1) | IL251285B (fr) |
| LT (1) | LT3230298T (fr) |
| MA (1) | MA41134B1 (fr) |
| MX (1) | MX379474B (fr) |
| MY (1) | MY194002A (fr) |
| PE (1) | PE20170679A1 (fr) |
| PH (1) | PH12017501061B1 (fr) |
| PL (1) | PL3230298T3 (fr) |
| PT (1) | PT3230298T (fr) |
| RS (1) | RS61612B1 (fr) |
| SG (1) | SG11201704512PA (fr) |
| SI (1) | SI3230298T1 (fr) |
| TW (1) | TWI733656B (fr) |
| UA (1) | UA124184C2 (fr) |
| WO (1) | WO2016091698A1 (fr) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2963717C (fr) * | 2014-12-08 | 2023-10-10 | F. Hoffmann-La Roche Ag | Composes 5-amino-6h-thiazolo [4,5-d]pour le traitement et la prophylaxide d'infections virales |
| CN107427514B (zh) * | 2015-03-16 | 2021-07-13 | 豪夫迈·罗氏有限公司 | 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗 |
| WO2016180743A1 (fr) * | 2015-05-12 | 2016-11-17 | F. Hoffmann-La Roche Ag | Nouvelle aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale |
| WO2017001307A1 (fr) | 2015-06-30 | 2017-01-05 | F. Hoffmann-La Roche Ag | Nouvelle aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale |
| TN2018000112A1 (en) | 2015-10-29 | 2019-10-04 | Novartis Ag | Antibody conjugates comprising toll-like receptor agonist |
| IL265921B2 (en) | 2016-10-14 | 2024-05-01 | Prec Biosciences Inc | Engineered meganucleases specific for recognition sequences in the hepatitis b virus genome |
| AU2018205995B2 (en) | 2017-01-06 | 2021-09-23 | F. Hoffmann-La Roche Ag | Solid forms of [(1S)-1 -[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-te trahydrofuran-2-yl]propyl] acetate |
| EP3568400B1 (fr) * | 2017-01-06 | 2025-11-19 | F. Hoffmann-La Roche AG | Procédé de préparation de composés 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione à substitution en position 3 |
| US12012421B2 (en) | 2017-07-07 | 2024-06-18 | Hoffmann-La Roche Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| US12012420B2 (en) | 2017-11-21 | 2024-06-18 | Hoffmann-La Roche, Inc. | Solid forms of [(1S)-1-[(2S,4R,5R)-5-(5-amino-2-oxo-thiazolo[4,5-d]pyrimidin-3-yl)-4-hydroxy-tetrahydrofuran-2-yl]propyl] acetate |
| WO2019118884A1 (fr) | 2017-12-15 | 2019-06-20 | Silverback Therapeutics, Inc. | Conjugué de construction d'anticorps-médicament pour le traitement de l'hépatite |
| US10966999B2 (en) | 2017-12-20 | 2021-04-06 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| CN111511754B (zh) | 2017-12-20 | 2023-09-12 | 捷克共和国有机化学与生物化学研究所 | 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸 |
| PL3759109T3 (pl) | 2018-02-26 | 2024-03-04 | Gilead Sciences, Inc. | Podstawione związki pirolizyny jako inhibitory replikacji hbv |
| WO2019195181A1 (fr) | 2018-04-05 | 2019-10-10 | Gilead Sciences, Inc. | Anticorps et leurs fragments qui se lient à la protéine x du virus de l'hépatite b |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| WO2019211799A1 (fr) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | Analogue de dinucléotide 2'3'-cyclique comprenant un nucléotide modifié par cyclopentanyle |
| CN112533607B (zh) * | 2018-05-25 | 2025-01-07 | 普利缪尼治疗学股份有限公司 | Tlr7激动剂 |
| EP4512407A3 (fr) | 2018-07-13 | 2025-09-24 | F. Hoffmann-La Roche AG | Oligonucléotides pour moduler l'expression de rtel1 |
| WO2020028097A1 (fr) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Formes solides d'acide (r)-11-(méthoxyméthyl)-12-(3-méthoxypropoxy)-3,3-diméthyl-8-0 x0-2,3,8,13b-tétrahydro-1h-pyrido[2,1-a] pyrrolo[1,2-c]phtalazine-7-carboxylique |
| TWI721623B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| TW202136261A (zh) | 2018-10-31 | 2021-10-01 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| JP7287708B2 (ja) | 2019-02-08 | 2023-06-06 | プロジェニア インコーポレイテッド | Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途 |
| EP3935066A1 (fr) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | Dinucléotides 3'3'-cycliques et leurs promédicaments |
| KR102707808B1 (ko) | 2019-03-07 | 2024-09-19 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭 |
| US11766447B2 (en) | 2019-03-07 | 2023-09-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| US11453681B2 (en) | 2019-05-23 | 2022-09-27 | Gilead Sciences, Inc. | Substituted eneoxindoles and uses thereof |
| MX2021015533A (es) | 2019-06-19 | 2022-02-10 | Silverback Therapeutics Inc | Anticuerpos anti-mesotelina e inmunoconjugados de los mismos. |
| US11339159B2 (en) * | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
| WO2021034804A1 (fr) | 2019-08-19 | 2021-02-25 | Gilead Sciences, Inc. | Formulations pharmaceutiques de ténofovir alafénamide |
| CN119770638A (zh) | 2019-09-30 | 2025-04-08 | 吉利德科学公司 | Hbv疫苗和治疗hbv的方法 |
| CA3163093A1 (fr) | 2019-11-26 | 2021-06-03 | Primmune Therapeutics, Inc. | Agonistes de tlr7 |
| US12410418B2 (en) | 2019-12-06 | 2025-09-09 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome |
| CN114828852A (zh) | 2019-12-24 | 2022-07-29 | 豪夫迈·罗氏有限公司 | 用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合 |
| EP4081639A1 (fr) | 2019-12-24 | 2022-11-02 | F. Hoffmann-La Roche AG | Association pharmaceutique d'un oligonucléotide thérapeutique ciblant le vhb et un agoniste de tlr7 pour le traitement du vhb |
| KR20220119616A (ko) | 2019-12-24 | 2022-08-30 | 에프. 호프만-라 로슈 아게 | Tlr7 효현제를 이용하여 바이러스 감염을 치료하는 방법 |
| JP7811014B2 (ja) | 2020-03-02 | 2026-02-04 | プロジェニア インコーポレイテッド | 病原菌外壁成分基盤の生病原体模倣ナノ粒子及びその製造方法 |
| US11718637B2 (en) | 2020-03-20 | 2023-08-08 | Gilead Sciences, Inc. | Prodrugs of 4′-C-substituted-2-halo-2′- deoxyadenosine nucleosides and methods of making and using the same |
| JP2023536954A (ja) | 2020-08-04 | 2023-08-30 | プロジェニア インコーポレイテッド | 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途 |
| CN116322751A (zh) | 2020-08-04 | 2023-06-23 | 蛋白科技先锋 | 包含能够动力学控制的佐剂的mRNA疫苗 |
| US20230355750A1 (en) | 2020-08-04 | 2023-11-09 | Progeneer Inc. | Kinetically acting adjuvant ensemble |
| CA3190794A1 (fr) | 2020-08-05 | 2022-02-10 | Soren Ottosen | Traitement par oligonucleotides des patients atteints d'hepatite b |
| JP7717832B2 (ja) | 2021-04-10 | 2025-08-04 | ジェンマブ エー／エス | Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法 |
| WO2022226317A1 (fr) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anticorps anti-cd70, leurs conjugués et leurs procédés d'utilisation |
| EP4337223A1 (fr) | 2021-05-13 | 2024-03-20 | Gilead Sciences, Inc. | Combinaison d'un composé de modulation de tlr8 et agent thérapeutique anti-arnsi de vhb |
| WO2022271659A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés modulant les diacylglycérol kinases |
| WO2022271677A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composés de modulation de la diacylglycérol kinase |
| CA3222277A1 (fr) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Composes modulant les diacylglycerol kinases |
| KR20240005901A (ko) | 2021-06-23 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| CA3234478A1 (fr) | 2021-11-11 | 2023-05-19 | Souphalone LUANGSAY | Combinaisons pharmaceutiques pour le traitement du vhb |
| CN121620516A (zh) * | 2023-08-08 | 2026-03-06 | 豪夫迈·罗氏有限公司 | 用于制备3-取代的5-氨基-6H-噻唑并[4,5-d]嘧啶-2,7-二酮化合物的方法 |
| AU2024353316A1 (en) | 2023-09-26 | 2026-03-26 | Genmab A/S | Ptk7 binding agents, conjugates thereof and methods of using the same |
| WO2025149661A1 (fr) | 2024-01-10 | 2025-07-17 | Genmab A/S | Agents de liaison à slitrk6, conjugués de ceux-ci et leurs procédés d'utilisation |
| WO2025181219A1 (fr) | 2024-02-29 | 2025-09-04 | Genmab A/S | Agents de liaison bispécifiques egfr et c-met, conjugués de ceux-ci et leurs procédés d'utilisation |
| WO2025240246A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec de la ribavirine |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
| WO2025240244A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies comprenant du bulévirtide et du lonafarnib destinées à être utilisées dans le traitement d'une infection par le virus de l'hépatite d |
| WO2025240242A1 (fr) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Polythérapies avec ribavirine |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5476659A (en) | 1982-11-09 | 1995-12-19 | The Scripps Research Institute | Cancerous B cell treatment using substituted nucleoside derivatives |
| US5166141A (en) | 1983-11-01 | 1992-11-24 | Scripps Clinic And Research Foundation | Immunostimulating 7-deaza-7-oxa- and 7-deaza-7-oxo-analogs of 8-substituted-guanine-9-(1'-beta-D-aldoglycosidyl) derivatives and methods of treating test animals |
| US5041426A (en) | 1987-12-21 | 1991-08-20 | Brigham Young University | Immune system enhancing 3-β-d-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and nucleotides |
| EP1072607A3 (fr) | 1996-10-16 | 2001-09-12 | ICN Pharmaceuticals, Inc. | Analogues de nucléosides-L-purine et leurs utilisations |
| ATE271063T1 (de) | 1996-10-16 | 2004-07-15 | Icn Pharmaceuticals | Purin-l-nukleoside, deren analoga und verwendungen |
| WO2005016235A2 (fr) | 2003-04-14 | 2005-02-24 | The Regents Of The University Of California | Utilisation combinee d'inhibiteurs de l'inosine monophosphate deshydrogenase (impdh) et d'agonistes du toll-like recepteur |
| EP1667694B1 (fr) | 2003-09-05 | 2010-04-28 | Anadys Pharmaceuticals, Inc. | Ligands tlr7 destines au traitement du virus de l'hepatite c |
| CN101212968B (zh) * | 2004-12-17 | 2011-11-16 | 安那迪斯药品股份有限公司 | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 |
| CN102504001B (zh) * | 2004-12-17 | 2015-02-25 | 安那迪斯药品股份有限公司 | 3,5-二取代的和3,5,7-三取代的-3H-噁唑并以及3H-噻唑并[4,5-d]嘧啶-2-酮化合物及其前药 |
| SG152296A1 (en) | 2005-11-21 | 2009-05-29 | Anadys Pharmaceuticals Inc | Novel process for the preparation of 5-amino-3h-thiazolo[4,5-d]pyrimidin-2- one |
| CL2007001427A1 (es) | 2006-05-22 | 2008-05-16 | Novartis Ag | Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po |
| MX2008016518A (es) * | 2006-06-22 | 2009-01-19 | Anadys Pharmaceuticals Inc | Profarmacos de 5-amino-3-(3'-desoxi-beta-d-ribofuranosil)-tiazolo[ 4,5-d]pirimidin-2,7-dion. |
| WO2008011406A2 (fr) | 2006-07-18 | 2008-01-24 | Anadys Pharmaceuticals, Inc. | Promédicaments à groupes fonctionnels carbonate et carbamate de thiazolo [4,5-d] pyrimidines |
| BRPI0717741A2 (pt) | 2006-10-17 | 2014-04-08 | Anadys Pharmaceuticals Inc | Compostos e respectivos método de preparação, método de redução de composto de sulfonil substituído, composição farmacêutica método de tratamento ou prevenção de doença |
| WO2009026292A1 (fr) * | 2007-08-20 | 2009-02-26 | Anadys Pharmaceuticals, Inc. | Procédés de dosage pour le traitement de pathologies |
| CA2963717C (fr) * | 2014-12-08 | 2023-10-10 | F. Hoffmann-La Roche Ag | Composes 5-amino-6h-thiazolo [4,5-d]pour le traitement et la prophylaxide d'infections virales |
| CN107427514B (zh) | 2015-03-16 | 2021-07-13 | 豪夫迈·罗氏有限公司 | 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗 |
| WO2016180743A1 (fr) | 2015-05-12 | 2016-11-17 | F. Hoffmann-La Roche Ag | Nouvelle aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale |
| WO2017001307A1 (fr) | 2015-06-30 | 2017-01-05 | F. Hoffmann-La Roche Ag | Nouvelle aminothiazolopyrimidinedione substituée pour le traitement et la prophylaxie d'une infection virale |
-
2015
- 2015-12-03 CA CA2963717A patent/CA2963717C/fr active Active
- 2015-12-03 MX MX2017007044A patent/MX379474B/es unknown
- 2015-12-03 PE PE2017000551A patent/PE20170679A1/es unknown
- 2015-12-03 WO PCT/EP2015/078439 patent/WO2016091698A1/fr not_active Ceased
- 2015-12-03 ES ES15804128T patent/ES2864223T3/es active Active
- 2015-12-03 HR HRP20210454TT patent/HRP20210454T1/hr unknown
- 2015-12-03 UA UAA201706823A patent/UA124184C2/uk unknown
- 2015-12-03 PT PT158041285T patent/PT3230298T/pt unknown
- 2015-12-03 EA EA201791011A patent/EA038744B1/ru unknown
- 2015-12-03 EP EP15804128.5A patent/EP3230298B1/fr active Active
- 2015-12-03 JP JP2017548325A patent/JP6817217B2/ja active Active
- 2015-12-03 SG SG11201704512PA patent/SG11201704512PA/en unknown
- 2015-12-03 CR CR20170237A patent/CR20170237A/es unknown
- 2015-12-03 MA MA41134A patent/MA41134B1/fr unknown
- 2015-12-03 RS RS20210297A patent/RS61612B1/sr unknown
- 2015-12-03 BR BR112017011941-2A patent/BR112017011941B1/pt active IP Right Grant
- 2015-12-03 CN CN201710845723.5A patent/CN107445980B/zh active Active
- 2015-12-03 CN CN201580018026.1A patent/CN106164079B/zh active Active
- 2015-12-03 AU AU2015359692A patent/AU2015359692B2/en active Active
- 2015-12-03 SI SI201531553T patent/SI3230298T1/sl unknown
- 2015-12-03 PL PL15804128T patent/PL3230298T3/pl unknown
- 2015-12-03 DK DK15804128.5T patent/DK3230298T3/da active
- 2015-12-03 MY MYPI2017702051A patent/MY194002A/en unknown
- 2015-12-03 HU HUE15804128A patent/HUE053704T2/hu unknown
- 2015-12-03 KR KR1020177015128A patent/KR102557560B1/ko active Active
- 2015-12-03 LT LTEP15804128.5T patent/LT3230298T/lt unknown
- 2015-12-03 KR KR1020237024143A patent/KR20230113824A/ko not_active Ceased
- 2015-12-03 US US14/958,619 patent/US9441008B2/en active Active
- 2015-12-07 TW TW104140978A patent/TWI733656B/zh active
-
2016
- 2016-07-11 US US15/207,338 patent/US10040815B2/en active Active
-
2017
- 2017-03-20 IL IL251285A patent/IL251285B/en unknown
- 2017-06-05 CL CL2017001426A patent/CL2017001426A1/es unknown
- 2017-06-07 PH PH12017501061A patent/PH12017501061B1/en unknown
-
2018
- 2018-07-02 US US16/025,170 patent/US10618929B2/en active Active
-
2020
- 2020-04-13 US US16/847,552 patent/US11180525B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41134B1 (fr) | Composés substitués de 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione pour le traitement et la prophylaxie des infections virales | |
| MA46038A (fr) | Composés de sulfonimidoylpurinone substitués dans la position 7 pour le traitement et la prophylaxie d'infection virale | |
| MA41338A (fr) | Composés de pyrazine pour le traitement de maladies infectieuses | |
| MA40225B1 (fr) | Composés dihydroisoquinolinone substitués | |
| EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
| TN2016000188A1 (fr) | Derives de purines 2,6-substitues et leur utilisation dans le traitement de troubles proliferatifs. | |
| EP4374858A3 (fr) | Dérivés de la benzimidazolone en tant qu'inhibiteurs du récepteur bcl6 | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA38323A1 (fr) | Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale | |
| WO2019035864A8 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins | |
| MA37712A2 (fr) | Inhibiteurs macrocycliques de virus flaviviridae | |
| MA37942A2 (fr) | Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b | |
| MA38315A1 (fr) | Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales | |
| MA37866B1 (fr) | Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur | |
| EP4371562A3 (fr) | Dérivés de la 2-quinolone en tant qu'inhibiteurs du récepteur bcl6 | |
| MA33745B1 (fr) | Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes | |
| MX380516B (es) | Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico | |
| MX2020012827A (es) | Compuestos tetrahidro-1h-pirazino[2,1-a]isoindolilquinolina para el tratamiento de enfermedades autoinmunes. | |
| NZ775222A (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
| UY37466A (es) | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa | |
| NZ746906A (en) | Oxaborole esters and uses thereof | |
| CR20200481A (es) | Derivados de pirazo-tetrahidroisoquinolina como moduladores positivos del receptor de dopamina di | |
| MA38009B1 (fr) | Composes d'azaindoline substitues qui ont une activite inhibitrice de la proteine d'apoptose pour leurs utilisations dans le traitement et/ou la prophylaxie du cancer | |
| MA39229A1 (fr) | Pyrrolidines, térahydrofuranes et cyclopentanes substitués utiles en tant qu'antagonistes des récepteurs des orexines | |
| PH12022551012A1 (en) | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease |